Special Issue "Non-Coding RNAs as Emerging Regulators of Signalling Pathways and Novel Therapeutic Targets in Human Cancers"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2020).
Interests: Cancer Research; Non-coding RNAs; Uro-gential cancers; Gastrointestinal cancers; Breast Cancer
Interests: cancer biology; metastasis; non-coding RNAs; RNA-binding proteins; functional genomics; genome engineering; CRISPR/Cas9
Special Issues and Collections in MDPI journals
Cancer is a devastating disease responsible for millions of deaths every year around the world. While mainly considered a genetic disease, epigenetic and post-transcriptional mechanisms emerged as significantly contributors to cancer development and progression.
The field of non-coding RNA research in cancer evolved about 20 years ago with the discovery of small regulatory non-coding RNAs called microRNAs. More recently, the class of long non-coding RNAs (lncRNAs), defined by RNA transcripts longer than 200 nucleotides in length with no open reading frame, has received much attention in the field of cancer biology. In fact, several lncRNAs have been shown to be not only dysregulated in different types of cancers but also function as direct effectors or mediators for many cancer signalling pathways. Hence, lncRNAs play a role in the regulation of cellular processes such as genome integrity, chromatin organization and gene expression control, translation regulation as well as signal transduction. The purpose of this Special Issue is to bring together a series of articles (both reviews and original research) from experts of non-coding RNA research that highlight the history and broaden our current understanding of the role of non-coding RNAs (both small and long) in cancer and their impact on signalling pathways. We invite contributions describing the role of non-coding RNAs in cancer development, cell fate decision as well as cell-cell communication, and immune evasion. In addition, manuscripts discussing state-of-the-art ncRNA technologies and developments in diagnostics and therapeutics of non-coding RNAs are invited as well.
Prof. Dr. Martin Pichler
Prof. Dr. Tony Gutschner
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.